Skip to main content

Hypereosinophilic Syndrome News

FDA Approves Nucala (mepolizumab) as the First and Only Biologic Treatment for Hypereosinophilic Syndrome (HES)

London UK 25 September 2020 – GlaxoSmithKline plc (GSK) today announced the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for the treatment of adult and pediatric patients...

Ask a question

To post your own question to this support group, sign in or create an account.